UCB Launches $2 Billion Biologics Manufacturing Campus in Georgia

UCB has dedicated a site in Rowen, Georgia, for a significant $2 billion biologics manufacturing campus, marking the company's inaugural manufacturing facility in the United States. With plans to commence operations around 2032 or 2033, this facility is anticipated to support the production of both newly approved and future biologic medicines by leveraging advanced manufacturing technologies, including artificial intelligence and automation.

The campus will span approximately 460,000 square feet and is situated on 79 acres within the innovative Rowen district—an initiative aimed at establishing a hub for biopharma and other knowledge-driven industries. UCB acquired the site from the Rowen Foundation, which is orchestrating the development of a broader 1,900-acre campus designed to foster collaboration and innovation across various sectors.

Impact on Employment and Local Economy

Upon completion, the biologics campus is projected to bring around 330 permanent jobs to the local economy. Furthermore, during the six- to seven-year construction period, UCB expects to generate over 1,000 construction jobs, contributing significantly to local employment opportunities and economic growth.

UCB's decision to establish its first U.S. manufacturing site in Georgia aligns with the state’s burgeoning life sciences ecosystem. The location offers a highly skilled workforce, robust infrastructure, and proximity to leading academic and research institutions, making it an attractive option for biopharmaceutical companies.

Collaboration and Community Support

The state of Georgia has shown its commitment to UCB's project by providing $174 million in incentives and infrastructure support. This investment forms part of a wider strategy outlined by the Georgia Life Sciences industry group, which recently launched a 10-year “Roadmap” to establish Georgia as a premier manufacturing hub for the Southeastern U.S. The presence of UCB's facility reinforces Georgia’s positioning in the biopharma sector, recently recognized by GEN as among the “Next 5 States” in its list of U.S. Biopharma Clusters.

UCB CEO Jean-Christophe Tellier articulated the significance of this investment: “Our manufacturing investment in the United States reflects our long-term commitment to patients, strengthening our ability to serve them while contributing to scientific innovation, highly skilled jobs, and economic growth in Georgia.” This commitment highlights UCB’s aim to impact the healthcare landscape positively.

Dedication Ceremony Highlights

The site dedication ceremony featured UCB executives and several prominent dignitaries, including Georgia Governor Brian Kemp and U.S. Department of Commerce Under Secretary Jeffrey Kessler. They participated in unveiling the Emmanuel Janssen Circle, a commemorative stonework installation named after the founder of UCB, celebrating the company’s roots and legacy in creating innovative therapies.

Katherine Raeymaekers, Consul General of Belgium in Atlanta, emphasized the collaborative efforts between Belgium and the United States, stating, “UCB’s new biomanufacturing campus builds on the entrepreneurial legacy of Baron Emmanuel Janssen, founder of UCB, while strengthening the transatlantic collaboration that drives economic growth, scientific innovation, and improving people’s lives.”

Catalyzing Future Innovation

UCB’s establishment of the biologics campus is not only a milestone for the company but also represents a potent catalyst for future innovations in the field of biopharmaceuticals. UCB is a major player in developing treatments for severe conditions, particularly in neurology and immunology. The company, headquartered in Brussels, has more than a decade-long history in the U.S., with over 2,000 employees across various functions.

In Georgia alone, UCB operates its Stateside headquarters and will continue to drive both research and manufacturing in the region. As the company prepares to embark on this extensive project, its focus remains on creating patient value and responding to serious healthcare needs.

UCB's investment strategy demonstrates a strong alignment with both local and national health priorities, highlighting the importance of biomanufacturing in ensuring timely access to biologic therapies. The completion of this facility is expected to enhance supply chain capabilities and further integrate UCB’s patient support initiatives, extending benefits from research and development through to manufacturing and delivery.

As UCB's project moves forward, stakeholders and community members will be watching closely to see how this investment influences both the local economy and the broader landscape of biopharmaceutical manufacturing in the United States.